. "Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist."@en . "53583-79-2"@en . "Amisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment."@en . . "investigational"@en . "Low (17%)"@en . . " "@en . . "4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide"@en . . "4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide"@en . . . . . "Amisulpridum"@en . . . . . . . . . . . . . . . . . . . . . . "Overdoses of amisulpride have been linked with torsades de pointes."@en . . . "approved"@en . . "Bioavailability is 48% following oral administration."@en . . . . . . "\"DrugSyn.org\":http://www.drugsyn.org/Amisulpride.htm"@en . . "Aminosultopride"@en . . "# Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G: A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002 Jan;17(1):1-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12404702 # Moller HJ: Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1101-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14642970 # Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14575800 # Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual \"atypical\" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002 Feb;159(2):180-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11823257 "@en . . "Amisulpride"@en . "Amisulprida"@en . . "Investigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression."@en . "Approximately 12 hours"@en . "Humans and other mammals"@en .